Beam Therapeutics (BEAM) reported second-quarter 2026 financial results, including a net loss of $122.7 million, or $1.18 per share, and license and collaboration revenue of $490,000.
The company said it ended the quarter with $1.2 billion in cash, cash equivalents and marketable securities, and expects its cash runway to support operating plans into mid-2029.
- Beam dosed the first patient in the global pivotal cohort of the BEAM-302 trial in alpha-1 antitrypsin deficiency.
- Updated BEAM-302 Phase 1/2 clinical data were selected for a late-breaking oral presentation at the ERS Congress 2026.
- Dosing is complete for all adult and adolescent patients in the Phase 1/2 BEACON trial of risto-cel in sickle cell disease.
- Beam expects to report updated BEACON data by year-end 2026 and submit a BLA for risto-cel as early as year-end 2026.
- The FDA cleared the IND application for BEAM-304 in phenylketonuria, and clinical trial start-up activities are underway.
$BEAM Insider Trading Activity
$BEAM insiders have traded $BEAM stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $BEAM stock by insiders over the last 6 months:
- LLC FMR has made 0 purchases and 2 sales selling 284,860 shares for an estimated $10,039,491.
- JOHN M. EVANS (CEO) has made 0 purchases and 7 sales selling 130,078 shares for an estimated $3,612,669.
- GIUSEPPE CIARAMELLA (President) has made 0 purchases and 2 sales selling 46,810 shares for an estimated $1,410,331.
- AMY SIMON (Chief Medical Officer) has made 0 purchases and 2 sales selling 23,367 shares for an estimated $593,722.
- CHRISTINE BELLON (Chief Legal Officer) sold 5,956 shares for an estimated $146,398
- BETHANY J CAVANAGH (SVP, Finance and Treasurer) sold 3,242 shares for an estimated $79,688
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BEAM Hedge Fund Activity
We have seen 129 institutional investors add shares of $BEAM stock to their portfolio, and 104 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAR1 CAPITAL MANAGEMENT, LLC added 1,446,375 shares (+inf%) to their portfolio in Q1 2026, for an estimated $34,467,116
- KYNAM CAPITAL MANAGEMENT, LP added 1,241,971 shares (+50.9%) to their portfolio in Q1 2026, for an estimated $29,596,168
- WOODLINE PARTNERS LP removed 993,066 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $23,664,762
- DEEP TRACK CAPITAL, LP added 820,765 shares (+inf%) to their portfolio in Q1 2026, for an estimated $19,558,829
- MARSHALL WACE, LLP removed 806,588 shares (-85.3%) from their portfolio in Q1 2026, for an estimated $19,220,992
- QUBE RESEARCH & TECHNOLOGIES LTD added 685,109 shares (+171.4%) to their portfolio in Q1 2026, for an estimated $16,326,147
- AMOVA ASSET MANAGEMENT AMERICAS, INC. removed 583,715 shares (-13.2%) from their portfolio in Q1 2026, for an estimated $13,909,928
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
